XTalks

DECEMBER 20, 2023

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

Pharma in Brief

JANUARY 15, 2024

2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders. Galderma ), markets two adapalene products in Canada: Differin ® , which contains 0.1% Differin XP TM , which contains a higher concentration of adapalene: 0.3% ( DIFFERIN XP ). The patentee, Galderma Canada Inc.

Dermatology 52

Dermatology Medicine Containment Production 52

XTalks

MARCH 6, 2023

The portfolio contains approximately forty-five commercial products, four products in the pipeline, and forty approved non-marketed products, many of which are generics focused on women’s health. The US has always been an important market for us,” said Chief Executive Officer of Dr. Reddy’s, Erez Israeli, in a statement.

Production 98

Production Branding Dermatology Hormones 98

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Pharma in Brief

JULY 7, 2020

2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders. Galderma ), markets two adapalene products in Canada: Differin ® , which contains 0.1% Differin XP TM , which contains a higher concentration of adapalene: 0.3% ( DIFFERIN XP ). This case concerns Canadian Patent No.

Medicine 40

Medicine Dermatology Containment Production 40

The Pharma Data

JANUARY 26, 2021

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Life Science 40

Life Science Production Marketing Dermatology 40

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98